Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban

Bibliographic Details
Main Authors:	Winkle, Roger A., Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Patrawala, Rob A.
Format:	Online
Language:	English
Published:	Oxford University Press 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178475/

Similar Items

Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes
by: Winkle, Roger A., et al.
Published: (2013)

Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients
by: Winkle, Roger A., et al.
Published: (2014)

Trends in atrial fibrillation ablation: have we maximized the current paradigms?
by: Winkle, Roger A., et al.
Published: (2012)

Physician-controlled costs: the choice of equipment used for atrial fibrillation ablation
by: Winkle, Roger A., et al.
Published: (2013)

Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation
by: Winkle, Roger A., et al.
Published: (2012)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-01-01)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
by: Wisløff, Torbjørn, et al.
Published: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
by: Yao, Xiaoxi, et al.
Published: (2016)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
by: Choi, Jiyoon C, et al.
Published: (2014)

Atrial Fibrillation Ablation without Interruption of Anticoagulation
by: Santangeli, Pasquale, et al.
Published: (2011)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
by: Pink, Joshua, et al.
Published: (2013)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
by: Gómez-Outes, Antonio, et al.
Published: (2013)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
by: Faye L. Norby, et al.
Published: (2017-09-01)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
by: Coleman, Craig I., et al.
Published: (2016)

Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
by: Leonie Stolz, et al.
Published: (2017-07-01)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
by: Ru San, Tan, et al.
Published: (2012)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
by: Tsantes, Argirios E., et al.
Published: (2016)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
by: Turpie, Alexander GG
Published: (2014)

Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin
by: Amini, Shahideh, et al.
Published: (2013)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
by: Benamer, Sufyan, et al.
Published: (2016)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
by: Breithardt, Günter, et al.
Published: (2016)

Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis
by: Providência, Rui, et al.
Published: (2014)

Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay
by: Imamura, Kimitake, et al.
Published: (2013)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
by: Laliberté, François, et al.
Published: (2015)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
by: Laliberté, François, et al.
Published: (2015)

Endoscopic submucosal dissection for early gastric cancer without interruption of warfarin and aspirin
by: Tounou, Shigetaka, et al.
Published: (2015)

Cost of dabigatran for atrial fibrillation
by: Gage, Brian F
Published: (2011)

Rivaroxaban in atrial fibrillation
by: Giorgi, Mariano A, et al.
Published: (2012)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
by: Abraham, Neena S, et al.
Published: (2015)

Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin
by: Shin, Dong Geum, et al.
Published: (2016)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
by: de Padua Mansur, Antonio, et al.
Published: (2012)

Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry
by: Vene, Nina, et al.
Published: (2016)

Promise and challenges of anticoagulation with dabigatran
by: Verma, Ashish, et al.
Published: (2012)

Safety and Efficacy of Switching Anticoagulation to Aspirin Three Months after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation
by: Uhm, Jae-Sun, et al.
Published: (2014)

Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report
by: Michele Scarano, et al.
Published: (2017-04-01)

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
by: You, Joyce H. S., et al.
Published: (2012)

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
by: Pink, Joshua, et al.
Published: (2011)

A comparison of dabigatran and warfarin for stroke prevention in elderly Asian population with nonvalvular atrial fibrillation: an audit of current practice in Malaysia
by: Yap, Swee Hien, et al.
Published: (2017)

A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
by: Sorensen, Sonja V., et al.
Published: (2013)

Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: Protocol
by: Duraes, Andre Rodrigues, et al.
Published: (2014)